IMS Health at ISPOR - Washington DC - May 2016
•
1 like•641 views
This document provides information about IMS Health's activities and participation at the ISPOR 21st Annual International Meeting from May 21-25, 2016 in Washington, DC. The document outlines IMS Health's educational symposium titled "How real-world evidence (RWE) can enable pharma to partner in healthcare delivery" as well as several research posters, presentations, and workshops led by IMS Health experts on topics related to real-world evidence and its use in healthcare. Members of IMS Health's global RWE Solutions team will be available at the company's booth throughout the event.
Report
Share
More Related Content
What's hot
What's hot (20)
Viewers also liked
Viewers also liked (11)
Similar to IMS Health at ISPOR - Washington DC - May 2016
Similar to IMS Health at ISPOR - Washington DC - May 2016 (20)
More from IMSHealthRWES
More from IMSHealthRWES (15)
Recently uploaded
Recently uploaded (20)
IMS Health at ISPOR - Washington DC - May 2016
- 1. ISPOR 21st Annual International Meeting 21-25 May 2016, Washington, DC, USA Join us for the IMS Health Symposium “How real-world evidence (RWE) can enable pharma to partner in healthcare delivery” Meet the largest expert community in RWE Discover the findings from our latest research IMS Health Real-World Evidence Solutions at ISPOR, Washington, DC, May 2016
- 2. It is a pleasure to bring you our program at the ISPOR 21st Annual International Meeting. We look forward to exploring the challenges of achieving “value, affordability, and patient-centeredness” in healthcare in today's complex and fast-changing landscape. IMS Health is committed to pushing the boundaries of real-world research to advance the achievement of these goals. Through our symposium, presentations, workshop and panel contributions, we are excited to share our innovative approaches that are extending the reach of real-world evidence (RWE), and our perspective on novel opportunities for improving healthcare globally. Please join us for a compelling line-up of activities at ISPOR. An overview of our participation at the event can be found in this brochure on pages 5 & 6. Key highlights are shown below. Members of our global RWE Solutions team will be on hand throughout the event at the IMS Health booth (Nos 64/65). We look forward to seeing you in Washington! Welcome to IMS Health at ISPOR, Washington, 2016 Live Sessions with IMS Health Educational Symposium 23 May, 12:30–13:30 How real-world evidence (RWE) can enable pharma to partner in healthcare delivery. Research Podium 23 May, 15:45–16:00 Real-world treatment patterns in patients with Type 2 diabetes newly initiated with antihyperglycemic medications in the United States. Workshop 24 May, 15:45–16:45 Real-world data and real-world evidence in Latin America: It takes two to tango. ISPOR Forum 24 May, 18:15–19:15 Use and management of Big Data in HEOR for creating best practices in Asia Pacific: Experiences and lessons learned in Australia, Japan, Singapore, S. Korea and Taiwan. Our RWE experts will be running demonstrations of IMS Health E360™ during ISPOR. This powerful suite of RWE applications allows researchers to answer even the most challenging questions in a standardized, intuitive way. Schedule your individual demonstration at the IMS Health booth or by emailing RWEinfo@imshealth.com or registering at http://response.us.imshealth.com/e360-demo-ispor/ Book a demonstration of IMS Health’s E360™ technology suite 2IMS Health Real-World Evidence Solutions
- 3. IMS Health Symposium Monday, 23 May “How real-world evidence (RWE) can enable pharma to partner in healthcare delivery” Containing healthcare costs has been a longstanding concern. In the USA, new drugs and technology innovations are further exacerbating alarm among providers as they try to meet required improvements in patient satisfaction, quality of care, population health and affordability. In their quest to realize greater value for their healthcare spend, they are seeking new tools to help. The application of RWD and advanced analytics to patient care provides innovative opportunities for improving healthcare delivery, effectiveness and efficiency. There is a well documented history of leveraging RWE in safety and drug utilization studies to meet regulatory requirements and in outcomes research studies to influence and support payer decisions. However, applying RWE to facilitate enhancements in patient care is more novel. In this symposium we will consider how RWE may be used to drive efficiencies and improvements in healthcare delivery, some challenges and limitations, and the way it is currently being applied by integrated delivery networks (IDNs). We will also explore new models for pharma and life sciences to accelerate engagement with healthcare delivery networks as partners in patient care. Our panel includes both provider representatives and senior experts from IMS Health. Agenda Introduction 12:30–12:35 Kenneth Park, MD, (Chair) Vice President, RWE Solutions, IMS Health, Plymouth Meeting, PA, USA Landscape of IDN and pharma RWE collaborations 12:35–12:45 Mitch DeKoven, MHSA, Principal, RWE Solutions, IMS Health, Fairfax, VA, USA Utilizing RWE to manage overall clinical care delivery 12:45–12:55 Oscar C. Marroquin, MD, FACC, Vice President, Clinical Analytics – UPMC Health Services Division; Assistant Professor of Medicine, Epidemiology and Clinical and Translational Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA Collaborative uses of RWE 12:55–13:05 Joseph G. Cacchione, MD, FACC, Chairman, Strategic Operations, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, USA What else can pharma do to make these partnerships valuable for healthcare delivery systems? 13:05–13:15 Jamie Thompson, BA, Vice President, RWE Solutions USA, IMS Health, Plymouth Meeting, PA, USA Moderated Q&A 13:15–13:30 Kenneth Park, MD (Chair) 3ISPOR 21st Annual International Meeting, 21-25 May 2016, Washington, DC, USA Proceedings from the symposium can be obtained from IMS Health. To receive a copy, please email Angelika Boucsein at Aboucsein@de.imshealth.com
- 4. Symposium Panel Kenneth Park, MD (Chair) is a Vice President, RWE Solutions at IMS Health where he leads the Product & Business Development team in the USA and is responsible for the overall US RWE strategy. In this role he develops new RWES products and services with a focus on win-win opportunities between life sciences, payers and providers. Dr. Park has 20 years of experience in the healthcare industry. He was previously with Anthem, Inc. where he designed and launched a next-generation Health Information Exchange in California (Cal INDEX). He also spent seven years at McKinsey & Company, Inc. where he co-led their Big Data in Healthcare work. This included heading the first RWE engagements in the pharmaceutical industry. Mitch DeKoven, MHSA is a Principal, RWE Solutions at IMS Health, leading teams in a variety of projects including value development plans, retrospective database studies and observational surveys. His background includes roles as an Associate Director of Reimbursement and Market Access at ValueMedics Research LLC, Manager of Reimbursement Services at United BioSource Corporation’s Center for Pricing & Reimbursement, Consultant with CHPS Consulting, and Program Manager of the Center for Cancer and Blood Disorders Children’s National Medical Center, a position he held after completing an administrative fellowship with the Johns Hopkins Health System. A past president of the board of directors of the Lupus Foundation of America Greater Washington Chapter, Mitch has authored several articles, serves on six editorial advisory boards and is a peer reviewer for a number of international healthcare journals. Oscar C. Marroquin, MD, FACC is a practicing cardiologist at the UPMC Heart and Vascular Institute, where he leads the Center’s clinical analytics efforts. Together with his colleagues he oversees the management and utilization of clinical data, applying different analytical techniques to understand the impact of healthcare delivery actions on outcomes. This includes developing predictive and prescriptive models of healthcare delivery based on analyses of large datasets. Dr. Marroquin’s academic career has focused on interventional cardiology and heart disease in women but he also has a background in the use of intravascular ultrasound and assessment of the coronary microvasculature. He is a member of the American Medical Association and American College of Physicians, and a fellow of the American College of Cardiology and Society of Cardiac Angiography and Interventions. Joseph G. Cacchione, MD, FACC is an interventional cardiologist at the Cleveland Clinic, Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Arnold and Sydell Miller Heart and Vascular Institute. He is also Chairman of Strategic Operations, Cleveland Clinic Heart and Vascular Institute, and as a leader in healthcare quality initiatives heads up Network Growth Strategy for the Cleveland Clinic Foundation. He previously spent more than 19 years in a private practice and served as Executive VP and Chief Quality Officer at Saint Vincent Health System in Erie, PA. Dr. Cacchione is a member of the ACC Board of Trustees and chairs its Partners in Quality Subcommittee. He also serves on the AQA Steering Committee, co-chairs the AQA Reporting Workgroup, and has participated in the Brooking Institution’s High-Value Health Care Project Data Set Workgroup. Recently, he was named to the National Priorities Partnership Advisory Council. Dr. Cacchione’s interests include payment reform, longitudinal care delivery and clinical quality improvement. Jamie Thompson, BA is a Vice President, leading the RWE Solutions business at IMS Health in the USA. This includes responsibility for HEOR, oncology, commercial patient, enterprise technology (evidence platforms) and informed media business. Jaime’s background spans consulting and sales roles at IMS Health and at various firms including Answerthink and Andersen. She has extensive experience in pharmaceutical marketing sciences, market research, sales operations and brand management, and strong expertise assisting companies with strategic analytical planning. She serves as an advisor in several specialty markets based on her skills leveraging secondary data and has worked with clients to design and implement a data warehouse environment to capture the full patient treatment paradigm, build an EMR repository for monitoring treatment progression, and re-engineer and roll out a use-by-indication algorithm used for incentive compensation. 4IMS Health Real-World Evidence Solutions
- 5. 5 24MAY IMS Health Activities 23 & 24 May 23MAY CODE TOPIC PRESENTERS TYPE HOW REAL-WORLD EVIDENCE (RWE) CAN ENABLE PHARMA TO PARTNER IN HEALTHCARE DELIVERY Park K, DeKoven M, Marroquin OC, Cacchione JG, Thompson J Educational Symposium EN1 REAL-WORLD TREATMENT PATTERNS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS NEWLY INITIATED WITH ANTIHYPERGLYCEMIC MEDICATIONS IN THE UNITED STATES Cai J, Burudpakdee C, Divino V Research Podium PCV9 CHARACTERIZATION OF STATIN EFFECTIVENESS USING REAL-WORLD DATA IN A CANADIAN POPULATION Shojaie S, McCurdy S, Thiele S, Ching Chau L, Martin L, Charland K, Dobson-Belaire W, Duclos M, Borrelli R Research Poster PCV108 TREATMENT PATTERNS AMONG PATIENTS PRESCRIBED PDE-5 INHIBITOR MONOTHERAPY FOR PULMONARY HYPERTENSION Yeaw J, Lickert C, Drake W, De AP, Wade RL Research Poster PND8 A NETWORK META-ANALYSIS ON COMPARATIVE EFFICACY AND SAFETY OF INVESTIGATIONAL AND APPROVED THERAPIES FOR THE TREATMENT OF NARCOLEPSY Taneja A, Saharia P, Chadha N, Rajput A, Goel A Research Poster PRM26 IDENTIFYING NON-RESPONDERS TO BRACE THERAPIES IN MULTIPLE SCLEROSIS USING ADVANCED PREDICTIVE MODELS Risson V, Rigg J, Bonzani I, Medin J, Olson MS Research Poster PRM45 LINKAGE ANALYSIS OF MULTIPLE-SCLEROSIS PATIENT DATA FROM SOCIAL-MEDIA SURVEYS AND CLAIMS DATABASES IDENTIFIES A REPRESENTATIVE POPULATION FOR REAL-LIFE OUTCOMES RESEARCH Risson V, Godge B, Bonzani I, Korn JR, Medin J, Olson MS Research Poster PRM57 LEVERAGING ELECTRONIC MEDICAL RECORD-BASED ANALYTICS TO OPTIMIZE THE DESIGN OF AN OBSERVATIONAL PROSPECTIVE STUDY OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE Wang X, Gerhardsson M, Sveréus A, Hiller J, Wong D, Nasuti P, Jenner H, Mckenney A, Kamauu AW, Flickinger KM Research Poster PRM79 A NOVEL METHOD USING PRESCRIPTION TREATMENT PATTERNS TO ESTIMATE HEART FAILURE PREVALENCE IN CANADA Jobin-Gervais K, Zaour N, Caron J, Borrelli R, Fischer AA Research Poster PRM85 THE COMPARISON OF CARDIOVASCULAR INCIDENCE PREDICTIONS IN TYPE 1 DIABETES UTILIZING ALTERNATIVE RISK PREDICTION MODELS Foos V, Lamotte M, McEwan P Research Poster PRM91 ASSESSING THE IMPACT OF SIMULATED TIME HORIZON ON PREDICTED INCREMENTAL QUALITY ADJUSTED LIFE YEARS IN TYPE 2 DIABETES Foos V, Lamotte M, McEwan P Research Poster PRM92 COMPARING DIRECT AND INDIRECT COSTS OF TYPE 2 DIABETES ACROSS THREE AGE RANGES IN THE UNITED STATES Foos V, Lamotte M, McEwan P Research Poster PRM94 QUANTIFYING THE HEALTH ECONOMIC BENEFIT OF KEY THERAPEUTIC OUTCOMES IN THE MANAGEMENT OF TYPE 2 DIABETES AND ASSESSING THEIR INTER-RELATIONSHIP McEwan P, Foos V, Lamotte M, Evans M Research Poster PRM190 DEVELOPMENT OF AN INNOVATIVE OBSERVATIONAL STUDY TO ASSESS MULTIPLE SCLEROSIS DISEASE PROGRESSION IN REAL WORLD CLINICAL PRACTICE Khan N, Weinstock-Guttman B, Medin J, Christoffersen P, Price J, Bonzani I, Zivadinov R Research Poster W10 REAL-WORLD DATA AND REAL-WORLD EVIDENCE IN LATIN AMERICA: IT TAKES TWO TO TANGO Nita ME, Vaz P, Ferraz A, Thompson D Workshop F10 USE AND MANAGEMENT OF BIG DATA IN HEALTH ECONOMICS AND OUTCOMES RESEARCH FOR CREATING BEST PRACTICES IN ASIA-PACIFIC: EXPERIENCES AND LESSONS LEARNED IN AUSTRALIA, JAPAN, SINGAPORE, SOUTH KOREA, AND TAIWAN Wee HL, Bae S, Crawford B, Roughead L, Chang C-J ISPOR Forum ISPOR 21st Annual International Meeting, 21-25 May 2016, Washington, DC, USA
- 6. 25MAY IMS Health Activities 24 & 25 May 24MAY CODE TOPIC PRESENTERS TYPE PCN56 UTILIZATION AND COST OF SUPPORTIVE CARE AMONG PATIENTS RECEIVING NAB-PACLITAXEL + GEMCITABINE VERSUS FOLFIRINOX FOR METATSTATIC PANCREATIC CANCER Patel M, Parisi M, Hill JW, De AP, Wade RL Research Poster PCN158 REAL-WORLD COMPARISON OF METASTATIC MELANOMA TREATMENTS BETWEEN ACADEMIC AND COMMUNITY HOSPITALS IN CANADA: A RETROSPECTIVE STUDY Lapierre M Research Poster PCN159 UTILIZATION OF RADIUM-223 DICHLORIDE (RA-223) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN CANADA: A REAL-WORLD RETROSPECTIVE STUDY Lapierre M, Fraelic A Research Poster PCN214 TREATMENT PATTERNS OF METASTATIC MELANOMA IN FIVE EUROPEAN COUNTRIES Burudpakdee C, Zhao Z, Seetasith A, Ma Q, Campos Tapias I, Barber BL Research Poster PMH8 COMPARATIVE EFFICACY AND TOLERABILITY OF LURASIDONE FOR THE MANAGEMENT OF BIPOLAR DEPRESSION: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS Ostacher MJ, Ng-Mak D, Patel P, Ntais D, Schlueter M, Loebel A Research Poster PDB31 ESTIMATING THE COST EFFECTIVENESS OF VILDAGLIPTIN VERSUS SULPHONYLUREA IN COMBINATION WITH METFORMIN: CLINICAL GUIDELINES VERSUS CLINICAL PRACTICE McEwan P, Gordon J, Foos V, Lamotte M, Evans M, Paldanius P Research Poster PDB32 COST EFFECTIVENESS OF TYPE 2 DIABETES TREATMENTS IN MIDDLE EASTERN COUNTRIES: AN ECONOMIC EVALUATION OF THE EDGE STUDY USING PATIENT LEVEL DATA McEwan P, Gordon J, Foos V, Lamotte M, Evans M, Paldanius P Research Poster PDB42 COST EFFECTIVENESS OF ALLOGENIC PANCREATIC ISLET TRANSPLANTATION VERSUS WHOLE PANCREAS TRANSPLANTATION IN THE UNITED KINGDOM De Francesco M, Johnson P, Lamotte M Research Poster PIN31 COST EFFECTIVENESS OF DE-ESCALATION FROM MICAFUNGIN VERSUS ESCALATION FROM FLUCONAZOLE FOR SYSTEMIC CANDIDA INFECTIONS IN CHINA Chen D, Wan X, Kruger E, Chen C, Yue X, Wang L, Jia S, Wu J Research Poster PMS59 ADHERENCE OF INITIAL BIOLOGIC DURING THE SECOND YEAR IN RHEUMATOID ARTHRITIS PATIENTS WITH ONE YEAR OF EFFECTIVE TREATMENT Stolshek B, De AP, Tang D, Wade S, Wade RL, Yeaw J Research Poster PSY17 BUDGET IMPACT MODEL FOR SELEXIPAG: TAKING A US PAYER PERSPECTIVE Beaudet A, Tsang Y, Hunsche E, Drake W, Bilir SP Research Poster PHP10 RADIOFREQUENCY TECHNOLOGY: VALUE IN THE ORTHOPAEDIC OPERATING ROOM Bilir SP, Munakata J, Borgman B, Ferrufino C, DeKoven M Research Poster PHP133 PCPA/CDR/PCODR CHANGES AND IMPACT TO MARKET ACCESS IN CANADA Millson B, Zhang Y Research Poster PHP180 PRESCRIPTION FACTORS ASSOCIATED WITH A DO NOT SUBSTITUTE PRESCRIPTION IN CANADA Fischer AA, Duclos M, Borrelli R Research Poster PMD14 BUDGET IMPACT OF CONTRAST MEDIA CHOICE AND CONTRAST INDUCED ACUTE KIDNEY INJURY IN HIGH-RISK PATIENTS UNDERGOING INVASIVE CORONARY ANGIOGRAPHY WITH OR WITHOUT PERCUTANEOUS CORONARY INTERVENTION FROM A US HOSPITAL PERSPECTIVE Todoran TM, Goldfarb S, Peña C, Ferrufino C, Kowal S, De Francesco M, Lamotte M, King A Research Poster PMD53 IMPROVEMENT IN ANTIHYPERTENSIVE AND CHOLESTEROL-LOWERING MEDICATION PERSISTENCE USING A MOBILE TECHNOLOGY APPLICATION Wade RL, Clancey B, Michaeli J Research Poster 6IMS Health Real-World Evidence Solutions
- 7. IMS Health Our Distinctive Approach IMS Health has taken a holistic approach to real-world evidence (RWE) in pursuit of the most robust and insightful views of patient outcomes. With the breadth and depth of our capabilities we are uniquely positioned to generate and use RWE globally. Applying the appropriate scientific and commercial lens and latest techniques to anonymous real-world data (RWD) is critical to realizing the value of RWE in healthcare decisions. IMS Health can uniquely support all elements of the RWE ecosystem – an environment where all the components of RWE come together for a consistent, insightful view of what really happens in healthcare. An environment which, for the first time, helps all functions realize its potential. Technology- Enabled Analytics Real-World Data Services and Engagement IMS HEALTH REAL-WORLD EVIDENCE SOLUTIONS Accesstherightreal-world da ta Analyzethedata Create datasets Apply the insights Nurturing your real-world success Real-World Data Identify and access the most appropriate data sources while ensuring patient privacy •The broadest and deepest collection of scientifically-validated, anonymous patient-level data assets complemented by custom data sourcing Technology-Enabled Analytics Create consistent data models empowering analyses and leveraging innovative technologies •Extraction, analysis and visualization of RWD with IMS Health’s E360TM technology suite •Sophisticated data linkage and interpretation Services and Engagement Analyze RWD using scientific rigor, clear governance and advanced analytic and processing capabilities •Market Access & HTA •Health Economics •Outcomes Research •Pharmacoepidemiology & Drug Safety •Commercial Analytics 7ISPOR 21st Annual International Meeting, 21-25 May 2016, Washington, DC, USA
- 8. ©2016 IMS Health Incorporated and its affiliates. All rights reserved. IMS HEALTH, IMS HEALTH INTELLIGENCE APPLIED and E360 are trademarks of IMS Health Incorporated. ORB1473 IMS Health Real-World Evidence Solutions is based in 20 countries worldwide with regional headquarters in RWEinfo@imshealth.com www.imshealth.com/rwe www.linkedin.com/company/ims-health-real-world-evidence www.twitter.com/IMSHealthRWE Europe 210 Pentonville Road London N1 9JY United Kingdom Tel: +44 (0) 20 3075 4800 The Americas 485 Lexington Avenue 26th Floor New York, NY 10017 USA Tel: +1 646 596 6053 Latin America Insurgentes Sur # 2375 5th Floor Col. Tizapan México D.F.- C.P. 01090 México Tel: +52 55 5089 5205 Asia-Pacific & Japan 8 Cross Street #21-01/02/03 Singapore 048424 Singapore Tel: +65 6412 7365 Toranomon Towers Office 4-1-28 Toranomon Minato-ku Tokyo 150-0001 Japan Tel: +81 3 5425 9541 IMS Health Real-World Evidence Solutions Bibliography Our research expertise and therapy area knowledge are captured in more than 3,500 publications, spanning virtually all therapy areas and projects completed in over 50 countries worldwide. In recognition of National Cancer Research Month in the USA, a special IMS Health RWE Solutions Oncology Bibliography will be available at ISPOR. This captures our wide range of HEOR and RWE papers and presentations published since 2010 across a variety of solid and hematological cancers globally. Pick up your copy from our booth to discover the research topics and innovative methodologies explored by our experts and tumor-specific specialists to inform key challenges in oncology today or visit www.imsrwebibliography.com to view our full database online. Oncology Bibliography IMS Health Real-World Evidence Solutions Published papers and presentationsin solid and hematological cancers2010–2016